


Edoxaban tosylate

Cat. No.:	HY-10264A
CAS No.:	480449-71-6
Molecular Formula:	C ₃₁ H ₃₈ ClN ₇ O ₇ S ₂
Molecular Weight:	720.26
Target:	Factor Xa; Thrombin
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (69.42 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.3884 mL	6.9419 mL	13.8839 mL
		5 mM		0.2777 mL	1.3884 mL	2.7768 mL
10 mM		0.1388 mL	0.6942 mL	1.3884 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.47 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.47 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.47 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K _i s of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research ^[1] .
IC₅₀ & Target	IC ₅₀ : 2.90 μM (platelet aggregation), K _i : 0.561 nM (free human FXa), 2.98 nM (prothrombinase), 0.715 nM (cynomolgus monkey FXa), 0.457 nM (rabbit FXa) ^[1]
In Vitro	Edoxaban tosylate (1, 1 and 5 minutes respectively) prolongs PT, TT and APTT of human plasma in a concentration-dependent manner ^[1] .

Edoxaban tosylate inhibits thrombin-induced platelet aggregation, with an IC₅₀ of 2.90 μM^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay^[1]

Cell Line:	Human, rat, cynomolgus monkey and rabbit plasma; Human platelet
Concentration:	
Incubation Time:	1 and 5 minutes
Result:	Antithrombin.

In Vivo

Edoxaban tosylate (0.5, 2.5 and 12.5 mg/kg; p.o.; once) significantly and dose-dependently reduces the thrombus formation and prolongs PT^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Slc: Wistar rats (210-240 g); Male New Zealand White rabbits(2.5-3.5 kg) (Both are venous stasis thrombosis model) ^[1] .
Dosage:	0.5, 2.5 and 12.5 mg/kg
Administration:	Oral administration; once
Result:	Inhibited exogenous FXa activity. Antithrombotic.

CUSTOMER VALIDATION

- Elife. 2022 Mar 23;11:e77444.
- Thromb Res. 2021 Jan;197:141-143.
- Molecules. 2023 Feb 28.
- PLoS One. 2024 May 15;19(5):e0292628.
- Virology. 2023 Jun 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA